Ferro-cerebro-cutaneous syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:397922OMIM:301072G31.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Ferro-cerebro-cutaneous syndrome (FCCS) is an extremely rare genetic disorder that affects multiple body systems, primarily the brain, skin, and other organs. The syndrome was first described by Dr. Ferro and colleagues, and it is characterized by a combination of neurological problems, skin abnormalities, and other developmental issues. Patients with this condition typically show signs from birth or early infancy, including brain abnormalities that can lead to intellectual disability, seizures, and delayed development. Skin findings may include unusual pigmentation, abnormal hair, or other cutaneous features. Because this syndrome is so rare, with only a handful of cases reported in the medical literature, our understanding of the full range of symptoms and the best approaches to treatment remains limited. Currently, there is no cure for Ferro-cerebro-cutaneous syndrome, and treatment focuses on managing individual symptoms. A team of specialists is usually needed to address the neurological, skin, and developmental aspects of the condition. Early intervention with therapies such as physical therapy, occupational therapy, and speech therapy can help maximize a child's developmental potential. Seizure management with anti-epileptic medications may also be necessary.

Also known as:

Key symptoms:

Intellectual disabilitySeizuresDelayed development or developmental regressionAbnormal brain structure visible on MRISkin pigmentation changesAbnormal hair growth or textureLow muscle toneDifficulty feeding in infancyMovement problemsGrowth delaysVision problemsDistinctive facial features

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Ferro-cerebro-cutaneous syndrome.

View clinical trials →

No actively recruiting trials found for Ferro-cerebro-cutaneous syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Ferro-cerebro-cutaneous syndrome community →

No specialists are currently listed for Ferro-cerebro-cutaneous syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Ferro-cerebro-cutaneous syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Ferro-cerebro-cutaneous syndromeForum →

No community posts yet. Be the first to share your experience with Ferro-cerebro-cutaneous syndrome.

Start the conversation →

Latest news about Ferro-cerebro-cutaneous syndrome

No recent news articles for Ferro-cerebro-cutaneous syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What specific tests have been done to confirm the diagnosis, and are there additional genetic tests that should be considered?,What type of seizures does my child have, and what is the best medication to control them?,What therapies (physical, occupational, speech) should we start, and how often?,Are there any clinical trials or research studies we could participate in?,What should I do if my child has a prolonged seizure or a medical emergency?,How often should we schedule follow-up appointments with each specialist?,What is the expected developmental trajectory, and how can we best support my child's progress?

Common questions about Ferro-cerebro-cutaneous syndrome

What is Ferro-cerebro-cutaneous syndrome?

Ferro-cerebro-cutaneous syndrome (FCCS) is an extremely rare genetic disorder that affects multiple body systems, primarily the brain, skin, and other organs. The syndrome was first described by Dr. Ferro and colleagues, and it is characterized by a combination of neurological problems, skin abnormalities, and other developmental issues. Patients with this condition typically show signs from birth or early infancy, including brain abnormalities that can lead to intellectual disability, seizures, and delayed development. Skin findings may include unusual pigmentation, abnormal hair, or other cu

How is Ferro-cerebro-cutaneous syndrome inherited?

Ferro-cerebro-cutaneous syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Ferro-cerebro-cutaneous syndrome typically begin?

Typical onset of Ferro-cerebro-cutaneous syndrome is neonatal. Age of onset can vary across affected individuals.